On the 10th, Whan In Pharm announced that the company signed an exclusive promotion and distribution agreement with Sanofi-Aventis for Arava Tablet, a rheumatoid arthritis treatment containing the active ingredient leflunomide, in Korea.

Whan In Pharm is recognized for its business specialization in the central nervous system (CNS) field. Through this agreement, Whan In Pharm plans to expand its business focus into areas beyond the CNS.

Arava Tablet is a drug for alleviating rheumatoid arthritis symptoms, active psoriatic arthritis symptoms, and others. The drug is steadily generating sales of around 6 billion won every year.

“We are pleased to announce our first